Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NovaDel Set To Submit Zolpidem Oral Spray In Second Half 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm also moves up timeline on sumatriptan oral spray submission to first half of 2008.

You may also be interested in...



No Simple Fix For Precipitate Problem; Hana Withdraws Zensana NDA

Hana also drops its SPA request for Marqibo, citing a change in FDA policy on open-label oncology trials.

Latest Imitrex Patent Settlement Protects GSK’s “Authorized” Generic

Dr. Reddy’s sumatriptan generic will likely hit the market several months before Cobalt’s launches in 2009.

Novadel’s NitroMist Application Moves Forward With Complete Response

The nitroglycerin NDA has an updated user fee date in early November.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS066255

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel